NurExone Announces Corporate Updates
Rhea-AI Summary
NurExone (OTCQB: NRXBF) announced three developments on March 11, 2026: a consulting agreement with Dr. Lars Bärfacker to support European scientific initiatives, finalist status in the Healthcare category of the 2026 BOLD Awards in Barcelona, and the closing of a non‑brokered private placement of 1,295,222 units at C$0.68 per unit for gross proceeds of approximately $880,750.96, subject to TSXV approval.
Each unit includes one common share and one warrant exercisable at C$0.85 for 36 months, with a potential acceleration provision if the 20‑day VWAP reaches C$1.70. Proceeds are for general working capital.
AI-generated analysis. Not financial advice.
Positive
- Private placement raised approximately $880,750.96 gross proceeds
- Consulting agreement with Dr. Lars Bärfacker strengthens European scientific expertise
- Named finalist in 2026 BOLD Awards Healthcare category (Barcelona, March 27, 2026)
Negative
- Issuance of 1,295,222 units causes potential shareholder dilution via shares and warrants
- Warrants exercisable at C$0.85 for 36 months could increase share count if exercised
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing
TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced several developments supporting its planned growth, increasing awareness in Europe, and the closing of a private placement.
Consulting Agreement with Former Bayer Scientist
The Company has signed a consulting agreement with Dr. Lars Bärfacker, an experienced medicinal chemist and former Principal Research Scientist at Bayer AG, to support aspects of NurExone’s European scientific and strategic initiatives. Dr. Bärfacker has more than two decades of experience in drug discovery and innovation and has contributed to the discovery of several clinical compounds, including Finerenone (Kerendia®), now approved for the treatment of cardiorenal diseases.
NurExone CEO, Dr. Lior Shaltiel, noted: “Lars brings many years of experience in the exosome field and a deep understanding of extracellular vesicle biology and its potential therapeutic applications, including his experience at Bayer. His perspective will be valuable as NurExone continues advancing its regenerative medicine platform globally, particularly in Europe.”
Finalist at the BOLD Awards
NurExone has also been named a finalist in the Healthcare category of the 2026 BOLD Awards, an international program recognizing innovation and leadership across industries. The awards ceremony and networking events will take place in Barcelona, Spain, on March 27, 2026, with NurExone CEO Dr. Lior Shaltiel expected to attend.
Private Placement
The Company is also pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 1,295,222 units (“Units”) at a price of C
"This financing strengthens our preclinical programs and advances the Company along its milestone-based roadmap," said Eran Ovadya, CFO of NurExone.
Each Unit consists of (i) one common share in the capital of the Company (each, a “Common Share”), and (ii) one Common Share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of C
Closing of the Offering is subject to receipt of all necessary regulatory approvals, including approval of the TSXV, and all securities issued under the Offering are subject to a statutory hold period of four months and one day from the closing date of the Offering.
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the Company’s roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Russo Partners LLC
Investor Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company’s ability to advance its European scientific and strategic initiatives; the expected attendance of Company representatives at the 2026 BOLD Awards events; the closing of the Offering and the receipt of all necessary regulatory approvals, including approval of the TSXV; the intended use of proceeds of the Offering; and statements regarding the Company’s platform technology and potential future applications.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: that the Company will be able to implement its initiatives as contemplated; that the BOLD Awards event will proceed as scheduled; that all conditions to closing of the Offering will be satisfied and all required regulatory approvals, including TSXV approval, will be obtained on a timely basis; and that the Company will use the proceeds of the Offering as described herein.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company not obtaining required regulatory approvals (including TSXV approval) on a timely basis or at all; changes to event scheduling or participation; the Company’s ability to execute on its plans and priorities; the Company’s ability to use the proceeds of the Offering as intended; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
